Loading stock data…
BNR
$17.09+0.06 (+0.38%)
Market ClosedLast close May 1
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Burning Rock Biotech Limited in the Healthcare sector is trading at $17.09. The stock is currently 59% below its 52-week high of $41.72, remaining 2.0% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why BNR maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$17.09
Potential Upside
5%
Whystock Fair Value$17.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Developm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$224.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.07%
Volume
Today's trading volume
37,995
Recent News
Brenntag Q4 Earnings Call Highlights
Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed and volumes weakening notably in the second half. On the company’s full-year results call, management
This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs
Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...
3 Promising Penny Stocks With Market Caps Over $40M
The U.S. stock market has been navigating a period of volatility, with major indices such as the Dow Jones Industrial Average and the S&P 500 experiencing fluctuations amid geopolitical tensions and economic policy discussions. Despite these broader market challenges, penny stocks remain an intriguing area for investors, representing smaller or newer companies that can offer potential value when backed by strong financials. In this context, we explore three penny stocks that exhibit financial...